MCL1 and plasma cell myeloma: Indeed, a recent report investigated the role of MCL-1 in 20 NSCLC cell lines using a potent MCL-1 inhibitor and showed that only 5% of NSCLC cell lines, in contrast with 68% of multiple myeloma cell lines, are highly sensitive to MCL-1 inhibition33.